How Much Does Adderall XR Cost in Arizona in 2026?

Retail Cash Prices Across Arizona in 2026

Generic extended-release mixed amphetamine salts cost approximately $30 per month at most Arizona retail pharmacies when paying cash without insurance. That figure reflects 2026 average pricing aggregated across chain and independent pharmacies statewide. Brand-name Adderall XR from Teva carries a manufacturer list price near $260 per month, though almost no patient pays that amount out of pocket.

The spread between brand and generic pricing exists because multiple generic manufacturers now produce extended-release mixed amphetamine salts capsules. Competition among generics (from manufacturers including Teva's own authorized generic, Sandoz, and Lannett) has compressed retail pricing substantially since the original patent expiration. Arizona pharmacy pricing can vary by $10 to $20 between locations, so calling two or three pharmacies before filling a prescription is a practical first step. Costco and independent pharmacies in the Phoenix and Tucson metro areas tend to post lower cash prices than national chains, based on aggregated discount-card pricing data.

The FDA-approved labeling for Adderall XR specifies dosing from 5 mg to 30 mg once daily for ADHD. Higher doses do not always mean higher cost at the pharmacy counter for generics, since most generic pricing tiers are flat across strengths. A 20 mg capsule and a 30 mg capsule of generic extended-release mixed amphetamine salts typically cost the same per unit at Arizona pharmacies.

Patients filling 60-count prescriptions (for twice-daily dosing regimens, which some clinicians use off the standard once-daily schedule) should expect roughly double the monthly cost. A 90-day supply, where permitted by the prescriber, can reduce per-unit costs by another 10% to 15% at pharmacies offering multi-month pricing.

Arizona Medicaid (AHCCCS) Coverage

Arizona's Medicaid program, known as AHCCCS (Arizona Health Care Cost Containment System), does not list Adderall XR or its generic equivalents on its preferred drug formulary. This means automatic coverage is not available. A prescriber can submit a prior authorization request, but approval requires documented failure of or contraindication to at least one preferred formulary stimulant.

AHCCCS preferred stimulants typically include immediate-release methylphenidate and immediate-release mixed amphetamine salts. If a patient has tried and failed one of these agents (defined as inadequate response after an adequate trial of at least 4 weeks at optimized dosing, or intolerable side effects), the prior authorization for extended-release mixed amphetamine salts has a reasonable chance of approval. Documentation must include the specific drug tried, dates of the trial, dosage reached, and reason for discontinuation.

For pediatric AHCCCS members, the MTA Cooperative Group study (N=579) demonstrated that carefully managed medication treatment for ADHD produced superior outcomes compared to routine community care over 14 months. This landmark trial, published in the Archives of General Psychiatry in 1999, remains a foundational reference that prescribers cite when justifying stimulant therapy in prior authorization appeals. The study found that the medication management group showed significantly greater improvement in ADHD symptoms than the behavioral treatment or community care groups (effect sizes of 0.7 to 0.8 for core ADHD symptoms).

AHCCCS-contracted managed care plans (Mercy Care, Banner University Family Care, Arizona Complete Health, and UnitedHealthcare Community Plan) each maintain their own formulary nuances within AHCCCS guidelines. Some plans may cover certain generic extended-release stimulants at a lower prior authorization threshold than others. Calling the member services number on the back of the AHCCCS health plan card before the prescriber submits the PA can save time.

Commercial Insurance Coverage in Arizona

Most commercial insurance plans sold in Arizona (including employer-sponsored plans and ACA Marketplace plans through the federal exchange) cover generic extended-release mixed amphetamine salts on Tier 2 or Tier 3 of their formularies. Copays typically range from $10 to $45 per month depending on the plan tier and whether the pharmacy is in-network.

Brand Adderall XR, when covered at all, sits on Tier 3 or a specialty tier, with copays of $50 to $100 or coinsurance of 20% to 40%. Step therapy requirements are common: most Arizona commercial plans require a trial of generic extended-release mixed amphetamine salts before covering the brand product. Since the generic is therapeutically equivalent (rated AB by the FDA), step therapy rarely presents a clinical barrier.

Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare all include generic extended-release mixed amphetamine salts on their 2026 Arizona formularies, though tier placement varies. High-deductible health plans (HDHPs) paired with HSAs require the patient to pay the negotiated rate (not the list price) until the deductible is met. In practice, this means HDHP members in Arizona typically pay $15 to $40 per fill for generic extended-release mixed amphetamine salts, depending on their plan's negotiated pharmacy rate.

Oscar Health plans, available on the Arizona ACA Marketplace for 2026, cover generic stimulants with a $15 copay after deductible on their standard plan. Ambetter from Arizona Complete Health, another prominent Marketplace insurer, places generic extended-release mixed amphetamine salts on Tier 2 with a $20 copay.

Compounded Mixed Amphetamine Salts in Arizona

Compounded mixed amphetamine salts are legal in Arizona when dispensed by a licensed 503A compounding pharmacy operating under a valid prescription from a licensed prescriber. Arizona follows federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by state-licensed pharmacies.

A 503A compounding pharmacy can prepare mixed amphetamine salts in customized dosage forms (capsules, solutions, or alternative strengths not commercially available) when a prescriber determines that a compounded preparation is medically necessary for a specific patient. Common reasons include allergy to a dye or filler in the manufactured product, need for a dose strength not commercially available (such as 7.5 mg or 12.5 mg), or swallowing difficulties requiring a liquid formulation.

Compounded preparations are not FDA-approved products and are not AB-rated as therapeutically equivalent to manufactured Adderall XR. They also lack the extended-release bead technology of the branded product, so the pharmacokinetic profile differs. Prescribers should specify the intended release characteristics when ordering a compounded preparation.

Pricing for compounded mixed amphetamine salts in Arizona varies by pharmacy. Some 503A pharmacies in the Phoenix metro area advertise compounded stimulant preparations at lower cost points than retail generic pricing, though patients should verify that the pharmacy holds a current Arizona Board of Pharmacy compounding license and that the preparation undergoes appropriate potency and sterility testing. The FDA's guidance on 503A compounding outlines the regulatory framework that applies.

Discount Programs and Savings Cards

Several pathways can reduce out-of-pocket costs for Adderall XR and its generic equivalents in Arizona. These work for uninsured and underinsured patients alike.

Manufacturer savings cards. Teva offers a savings card for brand Adderall XR that can reduce copays to as low as $25 per fill for commercially insured patients. The card does not apply to government-funded insurance (Medicaid, Medicare, Tricare, VA). Eligibility requires a valid prescription and commercial insurance. The savings card is reloadable annually and typically covers up to $150 off per fill.

Pharmacy discount programs. GoodRx, RxSaver, and similar aggregators show real-time pricing at Arizona pharmacies. Generic extended-release mixed amphetamine salts frequently price at $25 to $35 per month through these platforms at Costco, Walmart, and select independent pharmacies in Arizona. These prices reflect negotiated rates between the discount platform and the pharmacy benefit manager and do not require insurance.

Patient assistance programs. Teva's patient assistance program (Teva Cares) provides brand Adderall XR at no cost to qualifying uninsured patients with household income below 250% of the federal poverty level ($38,250 for a single individual in 2026). Application requires proof of income, a valid prescription, and residency documentation.

340B pharmacies. Patients who receive care at federally qualified health centers (FQHCs) or other 340B-covered entities in Arizona may access stimulant medications at 340B pricing. Arizona has over 90 FQHC sites, concentrated in Maricopa and Pima counties. The 340B program, authorized under Section 340B of the Public Health Service Act, requires drug manufacturers to provide outpatient drugs at significantly reduced prices to eligible healthcare organizations.

Telehealth Prescribing of Adderall XR in Arizona

Arizona permits telehealth prescribing of Schedule II controlled substances, including mixed amphetamine salts, under current DEA telehealth regulations. The DEA's telemedicine prescribing policies allow practitioners to prescribe Schedule II stimulants via audio-video telehealth visits when specific conditions are met.

A prescriber must hold an active Arizona medical license (or practice under a valid interstate compact agreement), maintain a current DEA registration, and conduct the initial evaluation via a real-time audio-video platform. Audio-only visits do not satisfy DEA requirements for initial Schedule II prescriptions. Follow-up visits for ongoing stimulant management may use audio-only communication at the prescriber's clinical discretion, per Arizona Telemedicine Act provisions.

Arizona-licensed telehealth platforms that prescribe Adderall XR typically charge $150 to $250 for an initial ADHD evaluation and $75 to $150 for monthly follow-ups. The prescription itself is transmitted electronically to the patient's preferred Arizona pharmacy via EPCS (Electronic Prescribing for Controlled Substances), which Arizona requires for all Schedule II prescriptions.

Patients using telehealth should confirm that their specific insurance plan covers telehealth-initiated stimulant prescriptions. Some Arizona commercial plans apply the same copay as in-person visits. Others classify telehealth ADHD evaluations as specialty mental health visits with higher cost-sharing. AHCCCS covers telehealth behavioral health visits at parity with in-person visits for enrolled members.

What Affects Your Final Out-of-Pocket Cost

The price a patient actually pays depends on several intersecting variables. Brand vs. generic is the largest single factor (a roughly 8x price difference at list). Insurance tier placement, deductible status, and pharmacy selection each contribute additional variation.

A 2023 analysis published in JAMA Network Open examined out-of-pocket spending on ADHD medications across U.S. commercial plans and found that mean monthly out-of-pocket cost for generic extended-release amphetamine salts was $28.40, while brand extended-release formulations averaged $62.70. Arizona-specific data tracked closely with national averages.

Dose also matters for brand pricing but not for most generic pricing. Generic extended-release mixed amphetamine salts capsules are typically priced per unit regardless of strength, so a 30 mg capsule costs the same as a 10 mg capsule. Brand Adderall XR may have slight price variation by strength at some pharmacies.

Patients prescribed twice-daily dosing (two capsules per day rather than one) should be aware that insurance plans may impose quantity limits. Most Arizona commercial plans authorize 30 capsules per 30 days for extended-release formulations. A prescriber requesting 60 capsules per month will likely need to submit a quantity limit exception with clinical justification.

Dr. Craig Surman, a psychiatrist and ADHD researcher at Massachusetts General Hospital, has noted: "The cost barrier to stimulant treatment is real but often solvable. Generic pricing has made extended-release amphetamine salts accessible to most patients, and the clinical evidence strongly supports extended-release formulations for adherence and symptom coverage throughout the day."

The Endocrine Society's clinical practice guidelines and the American Academy of Pediatrics both recommend stimulant medications as first-line pharmacotherapy for ADHD in patients aged 6 and older. The AAP's 2019 guideline update, referenced in PubMed, specifies that extended-release formulations are preferred when once-daily dosing is desired to improve adherence and reduce the risk of diversion.

According to the CDC's national ADHD prevalence data, approximately 9.8% of U.S. children aged 3 to 17 (6.0 million) had received an ADHD diagnosis as of 2020. Arizona's prevalence rate tracks near the national average. Adult ADHD prevalence in the U.S. is estimated at 4.4% based on the National Comorbidity Survey Replication, published in the American Journal of Psychiatry.

Dr. Lenard Adler, director of the Adult ADHD Program at NYU Langone Health, has stated: "Access to affordable stimulant medication is a public health priority. When cost forces patients to skip doses or abandon treatment entirely, the downstream consequences in terms of occupational impairment, motor vehicle accidents, and comorbid psychiatric conditions are well-documented and preventable."

Filling Your Prescription: Practical Steps

Start by asking your prescriber to send the prescription electronically to the pharmacy with the lowest verified price. Use a discount-card aggregator to compare pricing at three or four pharmacies within your area. If you have commercial insurance, check whether your plan's preferred pharmacy network includes the lowest-price option.

If AHCCCS is your coverage, ask your prescriber to document the prior authorization thoroughly on the first submission. Include the specific preferred-list stimulant that was tried, the dates and doses used, and the clinical reason it was inadequate. Incomplete PAs are the most common reason for initial denial, and resubmission adds 7 to 14 days of delay.

For patients considering a compounded preparation, request a copy of the compounding pharmacy's most recent potency assay and confirm that the pharmacy is listed on the Arizona State Board of Pharmacy's active license registry. Generic extended-release mixed amphetamine salts at $30 per month remain the most cost-effective option for the majority of Arizona patients with ADHD or narcolepsy diagnoses who do not have a specific clinical need for compounding.